focus -WSS

focus

author：knowledge 2025-09-05 05:51:53 - browse：639

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： In age of alternative facts, a scholarly course on calling out crap

explore

WSS

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

As demand for Covid shots wanes, Moderna seeks its next success

Trump demands the U.S. pay no more for drugs than other countries … again

What happened to the House vote on health price transparency?

'A game

Activists slam private health insurers over coverage restrictions

Wikipedia

focus

Wikipedia

Duchenne breakthrough therapy leaves behind pioneering families

Chamber of Commerce, DOJ clash in court over drug prices

Sports medicine is finally prioritizing gender equality

Jerome Adams on the need for new antivirals for Covid

How to save PrEP access — and even expand it

Transgender sports debate: Physicians say bans are health issue

Psychedelics group wrestles with new pharma identity

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

BioMarin wins approval for gene therapy to treat hemophilia A

DIEP, the 'gold standard' of breast reconstruction, is under threat

knowledge

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

ChatGPT in medicine: STAT answers readers' burning questions

Why the quest to eradicate polio has stumbled

Guidelines to prevent youth baseball injuries need more muscle

Why the drug industry's warnings on the IRA's impact fall short

Wikipedia

explore

explore

leisure time